Constitutive Activity and Inverse Agonists of G Protein-Coupled Receptors: A Current Perspective

Molecular Pharmacology

Volumn 64, Issue 6, 2003, Pages 1271-1276

  Milligan, Graeme ^a,b  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

11 CIS RETINAL; AGOUTI RELATED PROTEIN; ALPHA 1B ADRENERGIC RECEPTOR; BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CETIRIZINE; CHEMOKINE RECEPTOR; CLOPIDOGREL; DOPAMINE 1 RECEPTOR; DOPAMINE 5 RECEPTOR; FAMOTIDINE; FEXOFENADINE; G PROTEIN COUPLED RECEPTOR; LIGAND; LORATADINE; LOSARTAN; MELANOCORTIN RECEPTOR; METOPROLOL; MONTELUKAST; N ACETYL ALPHA INTERMEDIN[4-10]CYCLO[4 NORLEUCINE 5 ASPARTIC ACID 7 [3 (2 NAPHTHYL)ALANINE] 10 LYSINAMIDE]; OLANZAPINE; QUETIAPINE; RGS PROTEIN; RHODOPSIN; RISPERIDONE; THIOPERAMIDE; TOLTERODINE; UNINDEXED DRUG; VALSARTAN;

AGONIST; ANIMAL CELL; ANIMAL EXPERIMENT; CELL LINE; COMPETITIVE INHIBITION; CONCEPT FORMATION; CONTROLLED STUDY; DISULFIDE BOND; DRUG ACTIVITY; DRUG ANTAGONISM; ENZYME ACTIVITY; GENE MUTATION; HUMAN; HUMAN CELL; LIGAND BINDING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; RECEPTOR INTRINSIC ACTIVITY; SHORT SURVEY; SIGNAL TRANSDUCTION; TRANSGENIC ANIMAL;

ANIMALS; HUMANS; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION;

EID: 0347627709     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.64.6.1271     Document Type: Short Survey

References (75)

1. Adan RAH and Kas MJH (2003) Inverse agonism gains weight. Trends Pharmacol Sci 24:315-321.
2. Ai LS and Liao F (2002) Mutating the four extracellular cysteines in the chemokine receptor CCR6 reveals their differing roles in receptor trafficking, ligand binding and signaling. Biochemistry 41:8332-8341.
3. Alewijnse AE, Smit MJ, Hoffmann M, Verzijl D, Timmerman H, and Leurs R (1998) Constitutive activity and structural instability of the wild-type human H2 receptor. J Neurochem 71:799-807.
4. Ango F, Prezeau L, Muller T, Tu JC, Xiao B, Worley PF, Pin JP, Bockaert J, and Fagni L (2001) Agonist-independent activation of metabotropic glutamate receptors by the intracellular protein Homer. Nature (Lond) 411:962-965.
5. Backstrom JR, Price RD, Reasoner DT, and Sanders-Bush E (2000) Deletion of the serotonin 5-HT2C receptor PDZ recognition motif prevents receptor phosphorylation and delays resensitization of receptor responses. J Biol Chem 275:23620-23626.
6. Bais C, Santomasso B, Coso O, Arvanitakis L, Raaka EG, Gutkind JS, Asch AS, Cesarman E, Gershengorn MC, Mesri EA, et al. (1998) G-protein-coupled receptor of Kaposi's sarcoma-associated herpesvirus is a viral oncogene and angiogenesis activator. Nature (Lond) 391:86-89.
7. Barker EL, Westphal RS, Schmidt D, and Sanders-Bush E (1994) Constitutively active 5-hydroxytryptamine2C receptors reveal novel inverse agonist activity of receptor ligands. J Biol Chem 269:11687-11690.
8. Becamel C, Alonso G, Galeotti N, Demey E, Jouin P, Ullmer C, Dumuis A, Bockaert J, and Marin P (2002) Synaptic multiprotein complexes associated with 5-HT(2C) receptors: a proteomic approach. EMBO (Eur Mol Biol Organ) J 21:2332-2342.
9. Becamel C, Figge A, Poliak S, Dumuis A, Peles E, Bockaert J, Lubbert H, and Ullmer C (2001) Interaction of serotonin 5-hydroxytryptamine type 2C receptors with PDZ10 of the multi-PDZ domain protein MUPP1. J Biol Chem 276:12974-12982.
10. Bockaert J, Marin P, Dumuis A, and Fagni L (2003) The 'magic tail' of G protein-coupled receptors: an anchorage for functional protein networks. FEBS Lett 546:65-72.
11. Casarosa P, Menge WM, Minisini R, Otto C, van Heteren J, Jongejan A, Timmerman H, Moepps B, Kirchhoff F, Mertens T, et al. (2003) Identification of the first nonpeptidergic inverse agonist for a constitutively active viral-encoded G protein-coupled receptor. J Biol Chem 278:5172-5178.
12. Chalmers DT and Behan DP (2002) The use of constitutively active GPCRs in drug discovery and functional genomics. Nat Rev Drug Discov 1:599-608.
13. Chi JT, Chang HY, Wang NN, Chang DS, Dunphy N, and Brown PO (2003) Genomewide view of gene silencing by small interfering RNAs. Proc Natl Acad Sci USA 100:6343-6346.
14. Conley PB and Delaney SM (2003) Scientific and therapeutic insights into the role of the platelet P2Y12 receptor in thrombosis. Curr Opin Hematol 10:333-338.
15. de Ligt RA, Kourounakis AP, IJzerman AP (2000) Inverse agonism at G protein-coupled receptors: (patho)physiological relevance and implications for drug discovery. Br J Pharmacol 130:1-12.
16. Daeffler L and Landry Y (2000) Inverse agonism at heptahelical receptors: concept, experimental approach and therapeutic potential. Fundam Clin Pharmacol 14:73-87.
17. Decaillot FM, Befort K, Filliol D, Yue SY, Walker P, and Kieffer BL (2003) Opioid receptor random mutagenesis reveals a mechanisms for G protein-coupled receptor activation. Nature (Lond) Structural Biol 10:629-636.
18. Dubern B, Clement K, Pelloux V, Froguel P, Girardet JP, Guy-Grand B, and Tounian P (2001) Mutational analysis of melanocortin-4 receptor, agouti-related protein and alpha-melanocyte-stimulating hormone genes in severely obese children. J Pediatr 139:204-209.
19. 1-receptor transgenic mice. Mol Pharmacol 60:712-717.
20. Feng GJ, Kellett E, Scorer CA, Wilde J, White JH, and Milligan G (2003) Selective interactions between helix VIII of the human μ opioid receptors and the C terminus of periplakin disrupt G protein activation. J Biol Chem 278:33400-33407.
21. Foster LJ, De Hoog CL, and Mann M (2003) Unbiased quantitative proteomics of lipid rafts reveals high specificity for signaling factors. Proc Natl Acad Sci USA 100:5813-5818.
22. Fraile-Ramos A, Kohout TA, Waldhoer M, and Marsh M (2003) Endocytosis of the viral chemokine receptor US28 does not require beta-arrestins but is dependent on the clathrin-mediated pathway. Traffic 4:243-253.
23. Goodfellow VS and Saunders J (2003) The melanecortin system and its role in obesity and cachexia. Curr Top Med Chem 3:855-883.
24. Groblewski T, Maigret B, Larguier R, Lombard C, Bonnafous JC, and Marie J (1997) Mutation of Asn111 in the third transmembrane domain of the AT1A angiotensin II receptor induces its constitutive activation. J Biol Chem 272:1822-1826.
25. Guo HG, Sadowska M, Reid W, Tschachler E, Hayward G, and Reitz M (2003) Kaposi's sarcoma-like tumors in a human herpesvirus 8 ORF74 transgenic mouse. J Virol 77:2631-2639.
26. Haskell-Luevano C and Monck EK (2001) Agouti-related protein functions as an inverse agonist at a constitutively active brain melanecortin-4 receptor. Regul Pept 99:1-7.
27. Herrick-Davis K, Grinde E, and Teitler M (2000) Inverse agonist activity of atypical antipsychotic drugs at human 5-hydroxytryptamine2C receptors. J Pharmacol Exp Ther 295:226-232.
28. Hubbell WL, Altenbach C, Hubbell CM, and Ehorana HG (2003) Rhodopsin structure, dynamics, and activation: a perspective from crystallography, site-directed spin labeling, sulfhydryl reactivity and disulfide cross-linking. Adv Protein Chem 63:243-290.
29. Kjelsberg MA, Cotecchia S, Ostrowski J, Caron MG, and Lefkowitz RJ (1992) Constitutive activation of the alpha 1B-adrenergic receptor by all amino acid substitutions at a single site. Evidence for a region which constrains receptor activation. J Biol Chem 267:1430-1433.
30. Kreienkamp HJ (2002) Organisation of G-protein-coupled receptor signalling complexes by scaffolding proteins. Curr Opin Pharmacol 2:581-586.
31. Kuwasako K, Kitamura K, Uemura T, Nagoshi Y, Kato J, and Eto T (2003) The function of extracellular cysteines in the human adrenomedullin receptor. Hypertens Res 26 Suppl:S25-31.
32. Lee FJ, Xue S, Pei L, Vukusic B, Chery N, Wang Y, Wang YT, Niznik HB, Yu XM, and Liu F (2002) Dual regulation of NMDA receptor functions by direct protein-protein interactions with the dopamine D1 receptor. Cell 111:219-230.
33. Leurs R, Church MK, and Taglialatela M (2002) H1-antihistamines: inverse agonism, anti-inflammatory actions and cardiac effects. Clin Exp Allergy 32:489-498.
34. Levin MC, Marullo S, Muntaner O, Andersson B, and Magnusson Y (2002) The myocardium-protective Gly-49 variant of the β1-adrenergic receptor exhibits constitutive activity and increased desensitization and down-regulation. J Biol Chem 277:30429-30435.
35. Liu F, Wan Q, Pristupa ZB, Yu XM, Wang YT, and Niznik HB (2000) Direct protein-protein coupling enables cross-talk between dopamine D5 and gamma-aminobutyric acid A receptors. Nature (Lond) 403:274-280.
36. Lu XY (2001) Role of central melanocortin signaling in eating disorders. Psychopharmacol Bull 35:45-65.
37. Lubrano-Berthelier C, Durand E, Dubern B, Shapiro A, Dazin P, Weill J, Ferron C, Froguel P, and Vaisse C (2003) Intracellular retention is a common characteristic of childhood obesity-associated MC4R mutations. Hum Mol Genet 12:145-153.
38. Milano CA, Allen LF, Rockman HA, Dolber PC, McMinn TR, Chien KR, Johnson TD, Bond RA, and Lefkowitz RJ (1994) Enhanced myocardial function in transgenic mice overexpressing the beta 2-adrenergic receptor. Science (Wash DC) 264:582-586.
39. Miller WE, Houtz DA, Nelson CD, Kolattukudy PE, and Lefkowitz RJ (2003) GRK phosphorylation and β arrestin recruitment regulate the constitutive signaling activity of the human cytomegalovirus US28 GPCR. J Biol Chem 278:21663-21671.
40. Milligan G and IJzerman AP (2000) Stochastic multidimensional hypercubes and inverse agonism. Trends Pharmacol Sci 21:362-363.
41. Milligan G, Bond RA, and Lee M (1995) Inverse agonism: pharmacological curiosity or potential therapeutic strategy? Trends Pharmacol Sci 16:10-13.
42. Miserey-Lenkei S, Parnot C, Bardin S, Corvol P, and Clauser E (2002) Constitutive internalization of constitutively active agiotensin II AT(1A) receptor mutants is blocked by inverse agonists. J Biol Chem 277:5891-5901.
43. Morisset S, Rouleau A, Ligneau X, Gbahou F, Tardivel-Lacombe J, Stark H, Schunack W, Ganellin CR, Schwartz JC, and Arrang JM (2000) High constitutive activity of native H3 receptors regulates histamine neurons in brain. Nature (Lond) 408:860-864.
44. Nijenhuis WA, Garner KM, VanRozen RJ, and Adan RA (2003) Poor cell surface expression of human melanocortin-4 receptor mutations associated with obesity. J Biol Chem 278:22939-22945.
45. Nijenhuis WA, Oosterom J, and Adan RA (2001) AgRP(83-132) acts as an inverse agonist on the human-melanocortin-4 receptor. Mol Endocrinol 15:164-171.
46. Neubig RR and Siderovski DP (2002) Regulators of G-protein signalling as new central nervous system drug targets. Nat Rev Drug Discov 1:187-197.
47. Parnot C, Miserey-Lenkei S, Bardin S, Corvol P, and Clauser E (2002) Lessons from constitutively active mutants of G protein-coupled receptors. Trends Endocrinol Metab 13:336-343.
48. Pauwels PJ and Wurch T (1998) Review: amino acid domains involved in constitutive activation of G-protein-coupled receptors. Mol Neurobiol 17:109-135.
49. Pleskoff O, Treboute C, Brelot A, Heveker N, Seman M, and Alizon M (1997) Identification of a chemokine receptor encoded by human cytomegalovirus as a cofactor for HIV-1 entry. Science (Wash DC) 276:1874-1878.
50. Premont RT and Hall RA (2002) Identification of novel G protein-coupled receptor-interacting proteins. Methods Enzymol 343:611-621.
51. 2C receptor. J Pharmacol Exp Ther 299:83-89.
52. Rosenkilde MM, Kledal TN, Brauner-Osborne H, and Schwartz TW (1999) Agonists and inverse agonists for the herpesvirus 8-encoded constitutively active seven-transmembrane oncogene product, ORF-74. J Biol Chem 274:956-961.
53. Rosenkilde MM, Waldhoer M, Luttichau HR, and Schwartz TW (2001) Virally encoded 7TM receptors. Oncogene 20:1582-1593.
54. Rybin VO, Xu X, Lisanti MP, and Steinberg SF (2000) Differential targeting of beta-adrenergic receptor subtypes and adenylyl cyclase to cardiomyocyte caveolae. A mechanism to functionally regulate the cAMP signaling pathway. J Biol Chem 275:41447-41457.
55. Samama P, Bond RA, Rockman HA, Milano CA, and Lefkowitz RJ (1997) Ligand-induced overexpression of a constitutively active beta2-adrenergic receptor: pharmacological creation of a phenotype in transgenic mice. Proc Natl Acad Sci USA 94:137-141.
56. Samama P, Cotecchia S, Costa T, and Lefkowitz RJ (1993) A mutation-induced activated state of the beta 2-adrenergic receptor. Extending the ternary complex model. J Biol Chem 268:4625-4636.
57. Schwartz JC, Morisset S, Rouleau A, Ligneau X, Gbahou F, Tardivel-Lacombe J, Stark H, Schunack W, Ganellin CR, and Arrang JM (2003) Therapeutic implications of constitutive activity of receptors: the example of the histamine H3 receptor. J Neural Trasm Suppl 64:1-16.
58. Seifert R and Wenzel-Seifert K (2002) Constitutive activity of G-protein-coupled receptors: cause of disease and common property of wild-type receptors. Naunyn Schmiedeberg's Arch Pharmacol 366:381-416.
59. Semizarov D, Frost L, Sarthy A, Kroeger P, Halbert DN, and Fesik SW (2003) Specificity of short interfering RNA determined through gene expression signatures. Proc Natl Acad Sci USA 100:6347-6352.
60. Steinberg SF and Brunton LL (2001) Compartmentation of G protein-coupled signaling pathways in cardiac myocytes. Annu Rev Pharmacol Toxicol 41:751-773.
61. Strange PG (2002) Mechanisms of inverse agonism at G-protein-coupled receptors. Trends Pharmacol Sci 23:89-95.
62. Thomas U (2002) Modulation of synaptic signalling complexes by Homer proteins. J Neurochem 81:407-413.
63. Tiberi M and Caron MG (1994) High agonist-independent activity is a distinguishing feature of the dopamine D1B receptor subtype. J Biol Chem 269:27925-27931.
64. Tumova K, Iwasiow RM, and Tiberi M (2003) Insight into the mechanism of dopamine D1-like receptor activation. Evidence for a molecular interplay between the third extracellular loop and the cytoplasmic tail. J Biol Chem 278:8146-8153.
65. Vaisse C, Clement K, Durand E, Hercberg S, Guy-Grand B, and Froguel P (2000) Melanocortin-4 receptor mutations are a frequent and heterogeneous cause of morbid obesity. J Clin Investig 106:253-262.
66. 3 receptors in Chinese hamster ovary cells. J Pharmacol Exp Ther 290:908-916.
67. Vink T, Hinney A, van Elburg AA, van Goozen SH, Sandkuijl LA, Sinke RJ, Herpertz-Dahlmann BM, Hebebrand J, Remschmidt H, van Engeland H, et al. (2001) Association between an agouti-related protein gene polymorphism and anorexia nervosa. Mol Psychiatry 6:325-328.
68. Waldhoer M, Casarosa P, Rosenkilde MM, Smit MJ, Leurs R, Whistler JL, and Schwartz TW (2003) The carboxyl terminus of human cytomegalovirus-encoded 7 transmembrane receptor US28 camouflages agonism by nediating constitutive endocytosis. J Biol Chem 278:19473-19482.
69. Welsby PJ, Kellett E, Wilkinson G, and Milligan G (2002) Enhanced detection of receptor constitutive activity in the presence of regulators of G protein signalling: applications to the detection and analysis of inverse agonists and low efficacy partial agonists. Mol Pharmacol 61:1211-1221.
70. Wenzel-Seifert K, Liu HY, and Seifert R (2002) Similarities and differences in the coupling of human beta1- and beta2-adrenoceptors to Gs(alpha) splice variants. Biochem Pharmacol 64:9-20.
71. Wolff GL (2003) Regulation of yellow pigment formation in mice: a historical perspective. Pigment Cell Res 16:2-15.
72. Yang TY, Chen SC, Leach MW, Manfra D, Homey B, Wiekowski M, Sullivan L, Jenh CH, Narula SK, Chensue SW, et al. (2000) Transgenic expression of the chemokine receptor encoded by human herpesvirus 8 induces an angioproliferative disease resembling Kaposi's sarcoma. J Exp Med 191:445-454.
73. Yeo GS, Lank EJ, Farooqi IS, Keogh J, Challis BG, and O'Rahilly S (2003) Mutations in the human melanocortin-4 receptor gene associated with severe familial obesity disrupts receptor function through multiple molecular mechanisms. Hum Mol Genet 12:561-574.
74. Zimanyi IA and Pelleymounter MA (2003) The role of melanocortin peptides and receptors in regulation of energy balance. Curr Pharm Des 9:627-641.
75. 2 double knockout mice. Mol Pharmacol 58:887-894.